BackEvolent Health Overview

Evolent Health EBIT

Track Evolent Health's EBIT ($-510M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$8.79M
3.63% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$505.68M
341.1% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Evolent Health (EVH) FAQ

The latest EBIT for EVH is $-510M as of June 2026. That compares with $-110M in the prior-year period — down 341.1% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Evolent Health's historical trend and sector peers before judging valuation or financial health.

Over the past year, EVH's EBIT moved from $-110M to $-510M — a 341.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Evolent Health's operating scale or balance-sheet position.

Against Healthcare companies, EVH currently prints $-510M for EBIT, while the sector average sits near $23B. That is roughly 102.2% below the sector mean. Large gaps often invite a closer look at Evolent Health's growth, margins, and balance sheet.

A EBIT figure of $-510M for EVH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting EVH's EBIT ($-510M), review year-over-year change from $-110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.